Other Diagnostic Applications

The other main application area for predictive error analysis is in chemical process quantitative risk assessment (CPQRA) as a means of identifying human errors with significant risk consequences. In most cases, the generation of error modes in CPQRA is a somewhat unsystematic process, since it only considers errors that involve the failure to perform some pre-specified function, usually in an emergency (e.g., responding to an alarm within a time interval). The fact that errors of commission can arise as a result of diagnostic failures, or that poor interface design or procedures can also induce errors is rarely considered as part of CPQRA. However, this may be due to the fact that HEA techniques are not widely known in the chemical industry. The application of error analysis in CPQRA will be discussed further in Chapter 5. 

Ibopamine (2% eye drop) is recently introduced newer compound, producing dose dependent mydriasis endowed with very interesting characteristics rapid onset, marked pupil dilatation and rapid return to normal pupillary diameter. This rapid return to normal pupillary diameter after its diagnostic application in eye offers significant advantages compared to other currently available mydriatics. Ibopamine is well absorbed through the cornea, it is rapidly hydrolyzed by esterases to epinine and the mydriatic effect is correlated with the concentration of epinine in the aqueous humor. 

There are also some potentially new diagnostic applications for nanoscale dispersions of droplets or particles. For example, gold nanopartides can be bound to an oligonudeotide that is capable of binding to a target polynudeotide assodated with a particular disease. When these species come together and bind to each other their... 

These enzymes are extraordinarily abundant over 1200 restriction endonucleases had been isolated and characterized by early 1990. Of three classes defined, type II restriction enzymes, which generally cut within their recognition sequences, have found uses in a host of biomedical research and diagnostic applications to be discussed below. Type 1 enzymes cut nonspecifically many nucleotides distal to specific recognition sequences and contain both restriction enzyme and DNA modification (see below) activities on different subunits of multienzyme complexes. Type III restriction enzymes share the multienzyme aspeas of type I enzymes but vary in other properties such as ATPase activity and cofactor requirements. 

The lower limit of half-lives of radionuclides for diagnostic application is of the order of minutes. It is detennined by the time needed for synthesis of suitable compounds and for transport in the body to the place of application. On the other hand, half-lives > 1 d are less favourable, because of the longer radiation exposure of the patients and the risk of environmental contamination. 

The fact that most vegetable oils and fats are nontoxic allows them to be used as reliable excipients or carriers in many pharmaceutical formulations. Vegetable oils and fats have been approved as excipients to facilitate delivery of bioactive compounds, to act as fillers, binders, lubricants, solubilizers, emulsifiers, and emollients in a variety of delivery forms including tablets, capsules, suppositories, emulsions (enteral/parenteral), ointments, creams, and lotions. Other nondirect applications include artificial blood, gene delivery, diagnostic imaging, and medical devices (27). 

The Brookhaven Linear Isotope Producer (BLIP) at Brookhaven National Laboratory uses a linear accelerator that injects 200 MeV protons into the 33 GeV Alternating Gradient Synchrotron. The BLIP facility operates about 16 weeks per year and produces radioisotopes such as strontium-82, germanium-68, copper-67, and others that are used in medical diagnostic applications. 

Aside from the immunohistochemical detection of muscle-specific transcription factors as described earlier, no other genomic-immunohistochemical diagnostic applications are currently available. The PAX-FKHR chimeric transcripts are, to date, not detectable by immunohistochemistry. 

---